Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).| Pulmonary Hypertension News
The clinical trial is assessing the safety of Allyx Therapeutics' ALX-001 versus a placebo when given to adults twice daily for 28 days.| Parkinson's News Today